EMD Serono Research & Development Institute, Inc.
Clinical trials sponsored by EMD Serono Research & Development Institute, Inc., explained in plain language.
A research and development arm of Merck KGaA, focusing on biopharmaceutical innovations.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced colorectal cancer: first human trial launches Results expected Oct 2026 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Nov 2026 (estimated)
- New drug combo targets Hard-to-Treat cancers in early trial Results expected Feb 2027 (estimated)
- New cancer drug M3554 targets tough tumors in first human trial Results expected Apr 2027 (estimated)
-
Can an oral drug calm inflamed muscles in myositis?
Disease control Stopped earlyResearchers are testing an experimental oral drug called enpatoran in adults with dermatomyositis and polymyositis, two rare muscle-weakening diseases. Participants receive enpatoran or a placebo twice daily for up to 24 weeks while continuing their standard care. The trial measu…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo shows promise for kids with brain cancer
Disease control Stopped earlyThis early-phase trial is testing two drugs, avelumab and lenvatinib, together in children with brain tumors that have not responded to prior treatment. The study has two parts: first, finding a safe dose, and second, seeing if the combination can slow tumor growth. Only 17 child…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis early-stage study tested an experimental oral drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited and…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to stop head and neck cancer relapse in High-Risk patients
Disease control Stopped earlyThis study tested whether adding the drug xevinapant to standard radiation therapy could help prevent head and neck cancer from coming back after surgery. It included 166 people with high-risk cancer who could not take the usual chemotherapy drug cisplatin. The trial was stopped …
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental PARP inhibitor combo trial halted early after just 3 patients
Disease control Stopped earlyThis early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Head and neck cancer trial halted: did xevinapant fall short?
Disease control Stopped earlyThis phase 3 study tested whether adding the experimental drug Xevinapant to standard chemoradiotherapy could improve outcomes for people with locally advanced head and neck cancer. The trial planned to enroll 730 participants but was terminated early. The main goal was to see if…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Head and neck cancer drug combo safety trial halted early
Symptom relief Stopped earlyThis early-phase study aimed to see if adding the drug xevinapant to standard chemoradiotherapy is safe for people with advanced head and neck cancer that cannot be removed by surgery. The study planned to enroll 18 participants but was terminated early. The main focus was on sid…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC